Related Experiment Video
Updated: Dec 12, 2025

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
COVID-19 and immunosuppressive therapy in dermatology
Robert A Schwartz1, Swetalina Pradhan2, Dedee F Murrell3
1Department of Dermatology, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
Abstract:
Coronavirus 2019 (COVID 19) was first detected in December 2019 in China. It has become a pandemic. With concern about therapies that may decrease immunity and enhance the severity of an individual's COVID-19 infection, leading to a possibly fatal outcome, use of immunosuppressants has become an important concern. This work focuses on management of various skin diseases individuals lacking immunity to COVID-19 but requiring a systemic immunosuppressant, keeping in view the challenge of the COVID 19 pandemic and that our knowledge of this virus and its effects on the immune system are incomplete including knowledge as to an individual's immunity after COVID-19 infection.
Related Concept Videos
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
Skin Diseases and Disorders
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Tumor Immunotherapy
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

